In a previous study, we described the in vitro growth characteristics and pharmacological properties of two human multidrug resistant cell lines selected in DOX, HT1080/DR4 fibrosarcoma cells and LoVo/DR5 colon adenocarcinoma cells (Slovak et al., 1987 (Slovak et al., , 1988 . Despite identical selection strategies in vitro, the mechanism underlying the MDR phenotype of these two cell lines differ. LoVo/DR5 cells overexpress P-glycoprotein without gene amplification whereas HT1080/DR4 are drug resistant by a mechanism independent of P-glycoprotein (Slovak et al., 1988) . Chromosome 7 alterations were present in both MDR-resistant sublines (Slovak et al., 1987) . Of interest, a putative homogeneously staining region (HSR) of the short arm of chromosome 7 (p13-*.p22) was observed in HT1080/DR4 cells. This region of 7p is coincident with the chromosomal locus of the EGFR gene (Carlin & Knowles, 1982) . These data suggested that alterations in the EGFR might play a role in the acquired drug resistance of these two human MDR-resistant cell lines. In the present study, we have (i) confirmed the lack of P-glycoprotein in HTIO8O/DR4 cells by using a monoclonal antibody, C494, which identifies a different epitope on Pglycoprotein than the C219 monoclonal antibody used in our previous study, (ii) determined the tumorigenic potential of HT1O8O/DR4 cells, and (iii) determined if EGFR gene amplification or overexpression has occurred in either the HTIO80/ DR4 or LoVo/DR5 sublines.
To confirm our previous assertion that HTIO8O/DR4 cells do not overexpress P-glycoprotein (Slovak et al., 1988) , immunoblot analysis using purified cell membrane components and the C494 monoclonal antibody was performed. Plasma membrane purification, protein determinations, and immunoblotting procedures for the parental and DOX-resistant sublines were as previously described (Slovak et al., 1988) . The blots were probed with 125I-labelled C494 monoclonal antibody (a gift from Dr V. Ling, Toronto, Canada). A membrane preparation from the vinblastine-resistance (VBL) subline of the CEM human lymphoblastic leukaemia cell line, CEM/VBL,00, was used as a positive control (Beck et al., 1979) . The findings clearly confirmed that HTIO80/ DR4 cells do not overexpress P-glycoprotein, whereas CEM/ VBLIoo and LoVo/DR cells significantly overexpress this drug resistant-related protein (Figure 1 ). These data are in agreement with the molecular characterisation of these MDRresistant sublines (Slovak et al., 1988) . Of interest, a faint band which is readily apparent with a longer exposure, is observed in the LoVo parental and the LoVo/DR4 revertant subline maintained in drug-free (DF) medium over a 5 month period, supporting the suggestion that some colon carcinoma cells may be intrinsically resistant to chemotherapeutic agents by virtue of expression of mdrl (Fojo et al., 1987) .
To determine if the tumorigenic potential of HT1080 and HT108O/DR4 cells differed, I07 cells suspended in 0.125 ml phosphate buffered saline were injected subcutaneously in the right flank of female BALB/c nude mice. For each experiment, four mice per cell line were injected; the experiment was repeated twice. Mice were monitored daily. Tumours were measured in two dimensions and the area (mm2) was calculated. Tumours from both HT1080 and the DOX resistant HTlO8O/DR4 subline were observed within 2 to 4 weeks ( Table I ). The gross morphological appearance of the tumours differed; tumours derived from the HTIO8O/DR4 cells were small and firm whereas the HT1080 parental cell tumours were large and much softer in consistency. This observation is in keeping with the morphological changes noted in vitro during the acquisition of drug resistance; that is, the slender, spindle-shape appearance of HT1080 compared to the polyglonal and distorted forms of HTIO8O/DR4 cells. The longer latency period and slower growth of the HT1O8O/DR4 tumours is consistent with both the morphological changes and its longer doubling time in vitro (HtIO80, 19 h; HT1080/DR4, 30 h) (Slovak et al., 1987) . Although the data may suggest a degree of difference in the tumourigenic potential which may be attributed to the 'lower' level of drug resistance compared to other reported studies (Meyers et To determine if the EGFR expression was altered by either gene amplification or overexpression, high molecular weight DNA and total cellular RNA were isolated by standard methods (Maniatis et al., 1982 ) from HT1080, HT1O8O/DR4, LoVo and LoVo/DR5. Controls included the A431 cell line which has amplified and overexpressed EGFR (Merlino et al., 1984) and the CEM parental and CEM/VBL,oo variant that lacks EGFR overexpression/gene amplification, the latter containing amplified P-glycoprotein gene sequences (Hill et al., 1988) . For Southern (1975) blotting, 10 g of DNA from the various cell lines was digested with EcoRI, electrophoretically fractionated in 0.9% agarose gels, transferred to Gene Screen Plus (New England Nuclear) and hybridized to the cDNA pE7 probe which codes for a portion of the EGFR gene and is highly homologous to a portion of the v-erbB oncogene (Merlino et al., 1984) . Hybridisations and washings were performed under high-stringency conditions. RNA dot blots were performed as described by Thomas (1980) by applying RNA from each cell line onto nitrocellulose using a minifold apparatus (Schleicher and Schuell). For quantitation of the EGFR mRNA, serial dilutions of RNA were applied to Gene Screen Plus using a slot blot apparatus (BioRad) and hybridised with the pE7 probe. To control for variations in RNA loading, the blots were stripped and reprobed with a human actin cDNA probe.
The results of the EGFR Southern and RNA dot blots are presented in Figure 2 . Comparison of the DOX-resistant lines with their respective parental cell line demonstrates no EGFR gene amplification or significant mRNA overexpression in HT1080/DR4 and LoVo/DR5 cells. Although these data support the lack of EGFR gene amplification as previously described (Meyers et al., 1988) , these data fail to strengthen the extensive EGFR investigation of MDR-resistant human neuroblastoma cells with elevated EGFR levels resulting specifically from overexpressed EGFR mRNA (Meyers et al., 1988 In summary, our results indicate that while the cellular morphology of the HT1080/DR4 fibrosarcoma subline changed with the development of drug resistance, these cells retained their ability to form tumours in immunodeficient mice without a concomitant alteration of EGFR and despite the presence of a putative HSR near the normal cellular locus for EGFR on the short arm of chromosome 7. Although the relationship between drug resistance and tumourigenicity remains unclear, these data and those of others (Miyamoto, 1986; Mirski et al., 1987; Hill et al., 1988) support the idea that drug resistance and the loss of tumourigenicity should be regarded as two independent events (Remy et al., 1984) .
Several biochemi&al mechanisms in addition to P-glycoprotein have been proposed to explain the MDR phenotype. These include quantitative or qualitative alterations of DNA topoisomerase II, DNA repair enzymes and the drug-metabolising enzymes, acting either singly or in concert to manifest drug resistance. Identification and characterisation of the individual as well as the synergistic aspects of resistance mechanisms will be essential in the elucidation of clinical drug resistance. The present findings, and the inability of common chemosensitising agents (e.g. verapamil, nicardipine) to circumvent the drug resistance of HT1080/DR4 (Cole et al., 1989) , indicate that HT1080/DR4 will be a valuable model system of non-P-glycoprotein mediated drug resistance for both in vitro as well as in vivo experimental therapeutic investigations.
